Literature DB >> 26809239

BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling.

Rebecca L Harper1,2,3, Ann M Reynolds1, Claudine S Bonder4, Paul N Reynolds1,2,3.   

Abstract

BACKGROUND AND
OBJECTIVE: Pulmonary arterial hypertension (PAH) continues to be a fatal disease and is associated with downregulation of bone morphogenetic protein receptor type-2 (BMPR2). Our approach is to upregulate BMPR2 in the pulmonary vasculature allowing us to examine the changes in endothelial cell signalling and better understand what pathways are altered when disease is attenuated using this treatment approach.
METHODS: We used gene delivery of BMPR2 to human pulmonary endothelial cells to investigate downstream signalling, then assessed the impact of this approach on downstream signalling in vivo in rats with PAH using the monocrotaline (MCT) model.
RESULTS: Gene delivery of BMPR2 leads to an increase in BMPR2 protein expression, and this is associated with increased Smad1/5/8 and reduced Smad2/3 signalling. Additionally, we have found that BMPR2 modulation has effects on non-Smad signalling with increases found in phosphoinositide-3 kinase (PI3K) and a decrease in phosphorylated-p38-mitogen activated protein kinase (p38-MAPK) in vivo. These findings are associated with amelioration of PAH (reduced right ventricular, mean pulmonary artery pressures and Fulton Index).
CONCLUSION: These results indicate that the therapeutic effect of BMPR2 gene delivery on PAH is associated with a switch between TGF-β-Smad2/3 signalling to BMPR2-Smad1/5/8 signalling. This supports the further development of this treatment approach.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  adenovirus; bone morphogenetic receptor type 2; endothelium; gene therapy; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 26809239     DOI: 10.1111/resp.12729

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  14 in total

1.  Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension.

Authors:  Lisa K Blum; Richard R L Cao; Andrew J Sweatt; Matthew Bill; Lauren J Lahey; Andrew C Hsi; Casey S Lee; Sarah Kongpachith; Chia-Hsin Ju; Rong Mao; Heidi H Wong; Mark R Nicolls; Roham T Zamanian; William H Robinson
Journal:  Eur J Immunol       Date:  2018-02-22       Impact factor: 5.532

Review 2.  The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.

Authors:  Yasunobu Hayabuchi
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

3.  Hyperactive TGF-β Signaling in Smooth Muscle Cells Exposed to HIV-protein(s) and Cocaine: Role in Pulmonary Vasculopathy.

Authors:  Pranjali Dalvi; Himanshu Sharma; Tomara Konstantinova; Miles Sanderson; Amy O' Brien-Ladner; Navneet K Dhillon
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

4.  Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension.

Authors:  Guillermo Pousada; Vincenzo Lupo; Sheila Cástro-Sánchez; María Álvarez-Satta; Ana Sánchez-Monteagudo; Adolfo Baloira; Carmen Espinós; Diana Valverde
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

Review 5.  BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.

Authors:  Mar Orriols; Maria Catalina Gomez-Puerto; Peter Ten Dijke
Journal:  Cell Mol Life Sci       Date:  2017-04-26       Impact factor: 9.261

6.  Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2.

Authors:  Myung-Jin Kim; Seon Young Park; Hae Ryung Chang; Eun Young Jung; Anudari Munkhjargal; Jong-Seok Lim; Myeong-Sok Lee; Yonghwan Kim
Journal:  BMB Rep       Date:  2017-06       Impact factor: 4.778

7.  The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.

Authors:  Chris Happé; Kondababu Kurakula; Xiao-Qing Sun; Denielli da Silva Goncalves Bos; Nina Rol; Christophe Guignabert; Ly Tu; Ingrid Schalij; Karien C Wiesmeijer; Olga Tura-Ceide; Anton Vonk Noordegraaf; Frances S de Man; Harm Jan Bogaard; Marie-José Goumans
Journal:  Cells       Date:  2020-06-08       Impact factor: 6.600

8.  Association of the gene polymorphisms of BMPR2, ACVRL1, SMAD9 and their interactions with the risk of essential hypertension in the Chinese Han population.

Authors:  Yunpeng Chen; Chenxi Ye; Jingwen Chen; Dongming Lin; Hao Wang; Shen Wang
Journal:  Biosci Rep       Date:  2019-01-25       Impact factor: 3.840

Review 9.  Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.

Authors:  Benjamin J Dunmore; Rowena J Jones; Mark R Toshner; Paul D Upton; Nicholas W Morrell
Journal:  Cardiovasc Res       Date:  2021-09-28       Impact factor: 10.787

Review 10.  Molecular and Genetic Profiling for Precision Medicines in Pulmonary Arterial Hypertension.

Authors:  Shahood Fazal; Malik Bisserier; Lahouaria Hadri
Journal:  Cells       Date:  2021-03-13       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.